Wegovy: A Weight Loss Breakthrough for Heart Health

Wow! Wegovy cuts heart risks by 20% in a major trial.

First time a weight loss drug alone shows such protection.

Novo Nordisk studied Wegovy vs. placebo in 17,604 adults with heart disease and obesity.

This 5-year "Select" trial brought unexpected 20% risk reduction.

Type 2 diabetes drug Ozempic showed 26% reduction but not for non-diabetics.

Experts call it a "landmark" trial, awaiting full scientific results.

Novo Nordisk sees potential to reshape obesity treatment with Wegovy.

Positive results might boost insurance coverage for weight loss medications.

Wegovy costs $1,349/month before insurance, accessibility issues reported.

More data to come; watch out for scientific conference updates.

More data to come; watch out for scientific conference updates.

Heart Attack Truth And Myth | Magnesium in Cardiac Arrest

Read More